 | • レポートコード：MRC2Q12-00046 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：農業 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、不活性化豚パルボウイルスワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 不活性化豚パルボウイルスワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 不活性化豚パルボウイルスワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 不活性化豚パルボウイルスワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの不活性化豚パルボウイルスワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の不活性化豚パルボウイルスワクチンの売上および2028年までの予測に焦点を当てています。 不活性化豚パルボウイルスワクチンのグローバル主要企業には、Merck Animal Health、HIPRA、Zoetis、Ceva、Bioveta、Boehringer Ingelheim、Harbin Pharmaceutical Group、Wuhan Keqian Biology、DHN、China Animal Husbandy Industry、Qilu Animal Health Products Factorys、Shandong HuaHong Biological Engineering、Shanghai Hile Biological、Liaoning Yikang Biological、Jilin Zhengye Biological Productなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 不活性化豚パルボウイルスワクチン市場は、タイプとアプリケーションによって区分されます。世界の不活性化豚パルボウイルスワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 <107.0TCID50/mL、≥107.0TCID50/mL 【アプリケーション別セグメント】 雌豚、雌子豚、雄豚 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 不活性化豚パルボウイルスワクチン製品概要 - タイプ別市場（<107.0TCID50/mL、≥107.0TCID50/mL） - アプリケーション別市場（雌豚、雌子豚、雄豚） - 調査の目的 ・エグゼクティブサマリー - 世界の不活性化豚パルボウイルスワクチン販売量予測2017-2028 - 世界の不活性化豚パルボウイルスワクチン売上予測2017-2028 - 不活性化豚パルボウイルスワクチンの地域別販売量 - 不活性化豚パルボウイルスワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別不活性化豚パルボウイルスワクチン販売量 - 主要メーカー別不活性化豚パルボウイルスワクチン売上 - 主要メーカー別不活性化豚パルボウイルスワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（<107.0TCID50/mL、≥107.0TCID50/mL） - 不活性化豚パルボウイルスワクチンのタイプ別販売量 - 不活性化豚パルボウイルスワクチンのタイプ別売上 - 不活性化豚パルボウイルスワクチンのタイプ別価格 ・アプリケーション別市場規模（雌豚、雌子豚、雄豚） - 不活性化豚パルボウイルスワクチンのアプリケーション別販売量 - 不活性化豚パルボウイルスワクチンのアプリケーション別売上 - 不活性化豚パルボウイルスワクチンのアプリケーション別価格 ・北米市場 - 北米の不活性化豚パルボウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚パルボウイルスワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの不活性化豚パルボウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚パルボウイルスワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の不活性化豚パルボウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚パルボウイルスワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の不活性化豚パルボウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚パルボウイルスワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの不活性化豚パルボウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化豚パルボウイルスワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Merck Animal Health、HIPRA、Zoetis、Ceva、Bioveta、Boehringer Ingelheim、Harbin Pharmaceutical Group、Wuhan Keqian Biology、DHN、China Animal Husbandy Industry、Qilu Animal Health Products Factorys、Shandong HuaHong Biological Engineering、Shanghai Hile Biological、Liaoning Yikang Biological、Jilin Zhengye Biological Product ・産業チェーン及び販売チャネル分析 - 不活性化豚パルボウイルスワクチンの産業チェーン分析 - 不活性化豚パルボウイルスワクチンの原材料 - 不活性化豚パルボウイルスワクチンの生産プロセス - 不活性化豚パルボウイルスワクチンの販売及びマーケティング - 不活性化豚パルボウイルスワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 不活性化豚パルボウイルスワクチンの産業動向 - 不活性化豚パルボウイルスワクチンのマーケットドライバー - 不活性化豚パルボウイルスワクチンの課題 - 不活性化豚パルボウイルスワクチンの阻害要因 ・主な調査結果 |
The porcine parvovirus inactivated vaccine is used for preventing a porcine parvovirus disease caused by a porcine parvovirus.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Inactivated Porcine Parvovirus Vaccine estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Inactivated Porcine Parvovirus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Inactivated Porcine Parvovirus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Inactivated Porcine Parvovirus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Inactivated Porcine Parvovirus Vaccine include Merck Animal Health, HIPRA, Zoetis, Ceva, Bioveta, Boehringer Ingelheim, Harbin Pharmaceutical Group, Wuhan Keqian Biology and DHN, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
In terms of production side, this report researches the Inactivated Porcine Parvovirus Vaccine production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Inactivated Porcine Parvovirus Vaccine by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Report Scope
This latest report researches the industry structure, capacity, production, sales (consumption), revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Inactivated Porcine Parvovirus Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Inactivated Porcine Parvovirus Vaccine market. Further, it explains the major drivers and regional dynamics of the global Inactivated Porcine Parvovirus Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Merck Animal Health
HIPRA
Zoetis
Ceva
Bioveta
Boehringer Ingelheim
Harbin Pharmaceutical Group
Wuhan Keqian Biology
DHN
China Animal Husbandy Industry
Qilu Animal Health Products Factorys
Shandong HuaHong Biological Engineering
Shanghai Hile Biological
Liaoning Yikang Biological
Jilin Zhengye Biological Product
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on production, price, and value for the period 2017-2028.
Inactivated Porcine Parvovirus Vaccine Segment by Type
<107.0 TCID50/mL
≥107.0 TCID50/mL
Inactivated Porcine Parvovirus Vaccine Segment by Application
Sows
Gilts
Boars
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. This report analyzes the Inactivated Porcine Parvovirus Vaccine production by region/country, and the sales (consumption) by region/country. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Inactivated Porcine Parvovirus Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Inactivated Porcine Parvovirus Vaccine, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Inactivated Porcine Parvovirus Vaccine, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Inactivated Porcine Parvovirus Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Inactivated Porcine Parvovirus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Inactivated Porcine Parvovirus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Inactivated Porcine Parvovirus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck Animal Health, HIPRA, Zoetis, Ceva, Bioveta, Boehringer Ingelheim, Harbin Pharmaceutical Group, Wuhan Keqian Biology and DHN, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Inactivated Porcine Parvovirus Vaccine capacity, production/output of global and key producers (regions/countries). It provides a quantitative analysis of the capacity, production, and development potential of each producer in the next six years.
Chapter 3: Sales (consumption), revenue of Inactivated Porcine Parvovirus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Inactivated Porcine Parvovirus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by type, by application and by country, sales and revenue for each segment.
Chapter 8: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 9: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 10: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Porcine Parvovirus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 15: The main points and conclusions of the report.
1 Study Coverage
1.1 Inactivated Porcine Parvovirus Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Inactivated Porcine Parvovirus Vaccine Market Size by Type, 2017 VS 2021 VS 2028
1.2.2 <107.0 TCID50/mL
1.2.3 ≥107.0 TCID50/mL
1.3 Market by Application
1.3.1 Global Inactivated Porcine Parvovirus Vaccine Market Size by Application, 2017 VS 2021 VS 2028
1.3.2 Sows
1.3.3 Gilts
1.3.4 Boars
1.4 Study Objectives
1.5 Years Considered
2 Global Inactivated Porcine Parvovirus Vaccine Production
2.1 Global Inactivated Porcine Parvovirus Vaccine Production Capacity (2017-2028)
2.2 Global Inactivated Porcine Parvovirus Vaccine Production by Region: 2017 VS 2021 VS 2028
2.3 Global Inactivated Porcine Parvovirus Vaccine Production by Region
2.3.1 Global Inactivated Porcine Parvovirus Vaccine Historic Production by Region (2017-2022)
2.3.2 Global Inactivated Porcine Parvovirus Vaccine Forecasted Production by Region (2023-2028)
2.4 North America
2.5 Europe
2.6 China
2.7 Japan
3 Global Inactivated Porcine Parvovirus Vaccine Sales in Volume & Value Estimates and Forecasts
3.1 Global Inactivated Porcine Parvovirus Vaccine Sales Estimates and Forecasts 2017-2028
3.2 Global Inactivated Porcine Parvovirus Vaccine Revenue Estimates and Forecasts 2017-2028
3.3 Global Inactivated Porcine Parvovirus Vaccine Revenue by Region: 2017 VS 2021 VS 2028
3.4 Global Inactivated Porcine Parvovirus Vaccine Sales by Region
3.4.1 Global Inactivated Porcine Parvovirus Vaccine Sales by Region (2017-2022)
3.4.2 Global Sales Inactivated Porcine Parvovirus Vaccine by Region (2023-2028)
3.5 Global Inactivated Porcine Parvovirus Vaccine Revenue by Region
3.5.1 Global Inactivated Porcine Parvovirus Vaccine Revenue by Region (2017-2022)
3.5.2 Global Inactivated Porcine Parvovirus Vaccine Revenue by Region (2023-2028)
3.6 North America
3.7 Europe
3.8 Asia-Pacific
3.9 Latin America
3.10 Middle East & Africa
4 Competition by Manufactures
4.1 Global Inactivated Porcine Parvovirus Vaccine Production Capacity by Manufacturers
4.2 Global Inactivated Porcine Parvovirus Vaccine Sales by Manufacturers
4.2.1 Global Inactivated Porcine Parvovirus Vaccine Sales by Manufacturers (2017-2022)
4.2.2 Global Inactivated Porcine Parvovirus Vaccine Sales Market Share by Manufacturers (2017-2022)
4.2.3 Global Top 10 and Top 5 Largest Manufacturers of Inactivated Porcine Parvovirus Vaccine in 2021
4.3 Global Inactivated Porcine Parvovirus Vaccine Revenue by Manufacturers
4.3.1 Global Inactivated Porcine Parvovirus Vaccine Revenue by Manufacturers (2017-2022)
4.3.2 Global Inactivated Porcine Parvovirus Vaccine Revenue Market Share by Manufacturers (2017-2022)
4.3.3 Global Top 10 and Top 5 Companies by Inactivated Porcine Parvovirus Vaccine Revenue in 2021
4.4 Global Inactivated Porcine Parvovirus Vaccine Sales Price by Manufacturers
4.5 Analysis of Competitive Landscape
4.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
4.5.2 Global Inactivated Porcine Parvovirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5.3 Global Inactivated Porcine Parvovirus Vaccine Manufacturers Geographical Distribution
4.6 Mergers & Acquisitions, Expansion Plans
5 Market Size by Type
5.1 Global Inactivated Porcine Parvovirus Vaccine Sales by Type
5.1.1 Global Inactivated Porcine Parvovirus Vaccine Historical Sales by Type (2017-2022)
5.1.2 Global Inactivated Porcine Parvovirus Vaccine Forecasted Sales by Type (2023-2028)
5.1.3 Global Inactivated Porcine Parvovirus Vaccine Sales Market Share by Type (2017-2028)
5.2 Global Inactivated Porcine Parvovirus Vaccine Revenue by Type
5.2.1 Global Inactivated Porcine Parvovirus Vaccine Historical Revenue by Type (2017-2022)
5.2.2 Global Inactivated Porcine Parvovirus Vaccine Forecasted Revenue by Type (2023-2028)
5.2.3 Global Inactivated Porcine Parvovirus Vaccine Revenue Market Share by Type (2017-2028)
5.3 Global Inactivated Porcine Parvovirus Vaccine Price by Type
5.3.1 Global Inactivated Porcine Parvovirus Vaccine Price by Type (2017-2022)
5.3.2 Global Inactivated Porcine Parvovirus Vaccine Price Forecast by Type (2023-2028)
6 Market Size by Application
6.1 Global Inactivated Porcine Parvovirus Vaccine Sales by Application
6.1.1 Global Inactivated Porcine Parvovirus Vaccine Historical Sales by Application (2017-2022)
6.1.2 Global Inactivated Porcine Parvovirus Vaccine Forecasted Sales by Application (2023-2028)
6.1.3 Global Inactivated Porcine Parvovirus Vaccine Sales Market Share by Application (2017-2028)
6.2 Global Inactivated Porcine Parvovirus Vaccine Revenue by Application
6.2.1 Global Inactivated Porcine Parvovirus Vaccine Historical Revenue by Application (2017-2022)
6.2.2 Global Inactivated Porcine Parvovirus Vaccine Forecasted Revenue by Application (2023-2028)
6.2.3 Global Inactivated Porcine Parvovirus Vaccine Revenue Market Share by Application (2017-2028)
6.3 Global Inactivated Porcine Parvovirus Vaccine Price by Application
6.3.1 Global Inactivated Porcine Parvovirus Vaccine Price by Application (2017-2022)
6.3.2 Global Inactivated Porcine Parvovirus Vaccine Price Forecast by Application (2023-2028)
7 North America
7.1 North America Inactivated Porcine Parvovirus Vaccine Market Size by Type
7.1.1 North America Inactivated Porcine Parvovirus Vaccine Sales by Type (2017-2028)
7.1.2 North America Inactivated Porcine Parvovirus Vaccine Revenue by Type (2017-2028)
7.2 North America Inactivated Porcine Parvovirus Vaccine Market Size by Application
7.2.1 North America Inactivated Porcine Parvovirus Vaccine Sales by Application (2017-2028)
7.2.2 North America Inactivated Porcine Parvovirus Vaccine Revenue by Application (2017-2028)
7.3 North America Inactivated Porcine Parvovirus Vaccine Sales by Country
7.3.1 North America Inactivated Porcine Parvovirus Vaccine Sales by Country (2017-2028)
7.3.2 North America Inactivated Porcine Parvovirus Vaccine Revenue by Country (2017-2028)
7.3.3 United States
7.3.4 Canada
8 Europe
8.1 Europe Inactivated Porcine Parvovirus Vaccine Market Size by Type
8.1.1 Europe Inactivated Porcine Parvovirus Vaccine Sales by Type (2017-2028)
8.1.2 Europe Inactivated Porcine Parvovirus Vaccine Revenue by Type (2017-2028)
8.2 Europe Inactivated Porcine Parvovirus Vaccine Market Size by Application
8.2.1 Europe Inactivated Porcine Parvovirus Vaccine Sales by Application (2017-2028)
8.2.2 Europe Inactivated Porcine Parvovirus Vaccine Revenue by Application (2017-2028)
8.3 Europe Inactivated Porcine Parvovirus Vaccine Sales by Country
8.3.1 Europe Inactivated Porcine Parvovirus Vaccine Sales by Country (2017-2028)
8.3.2 Europe Inactivated Porcine Parvovirus Vaccine Revenue by Country (2017-2028)
8.3.3 Germany
8.3.4 France
8.3.5 U.K.
8.3.6 Italy
8.3.7 Russia
9 Asia Pacific
9.1 Asia Pacific Inactivated Porcine Parvovirus Vaccine Market Size by Type
9.1.1 Asia Pacific Inactivated Porcine Parvovirus Vaccine Sales by Type (2017-2028)
9.1.2 Asia Pacific Inactivated Porcine Parvovirus Vaccine Revenue by Type (2017-2028)
9.2 Asia Pacific Inactivated Porcine Parvovirus Vaccine Market Size by Application
9.2.1 Asia Pacific Inactivated Porcine Parvovirus Vaccine Sales by Application (2017-2028)
9.2.2 Asia Pacific Inactivated Porcine Parvovirus Vaccine Revenue by Application (2017-2028)
9.3 Asia Pacific Inactivated Porcine Parvovirus Vaccine Sales by Region
9.3.1 Asia Pacific Inactivated Porcine Parvovirus Vaccine Sales by Region (2017-2028)
9.3.2 Asia Pacific Inactivated Porcine Parvovirus Vaccine Revenue by Region (2017-2028)
9.3.3 China
9.3.4 Japan
9.3.5 South Korea
9.3.6 India
9.3.7 Australia
9.3.8 China Taiwan
9.3.9 Indonesia
9.3.10 Thailand
9.3.11 Malaysia
10 Latin America
10.1 Latin America Inactivated Porcine Parvovirus Vaccine Market Size by Type
10.1.1 Latin America Inactivated Porcine Parvovirus Vaccine Sales by Type (2017-2028)
10.1.2 Latin America Inactivated Porcine Parvovirus Vaccine Revenue by Type (2017-2028)
10.2 Latin America Inactivated Porcine Parvovirus Vaccine Market Size by Application
10.2.1 Latin America Inactivated Porcine Parvovirus Vaccine Sales by Application (2017-2028)
10.2.2 Latin America Inactivated Porcine Parvovirus Vaccine Revenue by Application (2017-2028)
10.3 Latin America Inactivated Porcine Parvovirus Vaccine Sales by Country
10.3.1 Latin America Inactivated Porcine Parvovirus Vaccine Sales by Country (2017-2028)
10.3.2 Latin America Inactivated Porcine Parvovirus Vaccine Revenue by Country (2017-2028)
10.3.3 Mexico
10.3.4 Brazil
10.3.5 Argentina
10.3.6 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Market Size by Type
11.1.1 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Sales by Type (2017-2028)
11.1.2 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Revenue by Type (2017-2028)
11.2 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Market Size by Application
11.2.1 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Sales by Application (2017-2028)
11.2.2 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Revenue by Application (2017-2028)
11.3 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Sales by Country
11.3.1 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Sales by Country (2017-2028)
11.3.2 Middle East and Africa Inactivated Porcine Parvovirus Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey
11.3.4 Saudi Arabia
11.3.5 UAE
12 Corporate Profiles
12.1 Merck Animal Health
12.1.1 Merck Animal Health Corporation Information
12.1.2 Merck Animal Health Overview
12.1.3 Merck Animal Health Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.1.4 Merck Animal Health Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.1.5 Merck Animal Health Recent Developments
12.2 HIPRA
12.2.1 HIPRA Corporation Information
12.2.2 HIPRA Overview
12.2.3 HIPRA Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.2.4 HIPRA Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.2.5 HIPRA Recent Developments
12.3 Zoetis
12.3.1 Zoetis Corporation Information
12.3.2 Zoetis Overview
12.3.3 Zoetis Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.3.4 Zoetis Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.3.5 Zoetis Recent Developments
12.4 Ceva
12.4.1 Ceva Corporation Information
12.4.2 Ceva Overview
12.4.3 Ceva Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.4.4 Ceva Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.4.5 Ceva Recent Developments
12.5 Bioveta
12.5.1 Bioveta Corporation Information
12.5.2 Bioveta Overview
12.5.3 Bioveta Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.5.4 Bioveta Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.5.5 Bioveta Recent Developments
12.6 Boehringer Ingelheim
12.6.1 Boehringer Ingelheim Corporation Information
12.6.2 Boehringer Ingelheim Overview
12.6.3 Boehringer Ingelheim Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.6.4 Boehringer Ingelheim Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.6.5 Boehringer Ingelheim Recent Developments
12.7 Harbin Pharmaceutical Group
12.7.1 Harbin Pharmaceutical Group Corporation Information
12.7.2 Harbin Pharmaceutical Group Overview
12.7.3 Harbin Pharmaceutical Group Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.7.4 Harbin Pharmaceutical Group Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.7.5 Harbin Pharmaceutical Group Recent Developments
12.8 Wuhan Keqian Biology
12.8.1 Wuhan Keqian Biology Corporation Information
12.8.2 Wuhan Keqian Biology Overview
12.8.3 Wuhan Keqian Biology Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.8.4 Wuhan Keqian Biology Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.8.5 Wuhan Keqian Biology Recent Developments
12.9 DHN
12.9.1 DHN Corporation Information
12.9.2 DHN Overview
12.9.3 DHN Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.9.4 DHN Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.9.5 DHN Recent Developments
12.10 China Animal Husbandy Industry
12.10.1 China Animal Husbandy Industry Corporation Information
12.10.2 China Animal Husbandy Industry Overview
12.10.3 China Animal Husbandy Industry Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.10.4 China Animal Husbandy Industry Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.10.5 China Animal Husbandy Industry Recent Developments
12.11 Qilu Animal Health Products Factorys
12.11.1 Qilu Animal Health Products Factorys Corporation Information
12.11.2 Qilu Animal Health Products Factorys Overview
12.11.3 Qilu Animal Health Products Factorys Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.11.4 Qilu Animal Health Products Factorys Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.11.5 Qilu Animal Health Products Factorys Recent Developments
12.12 Shandong HuaHong Biological Engineering
12.12.1 Shandong HuaHong Biological Engineering Corporation Information
12.12.2 Shandong HuaHong Biological Engineering Overview
12.12.3 Shandong HuaHong Biological Engineering Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.12.4 Shandong HuaHong Biological Engineering Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.12.5 Shandong HuaHong Biological Engineering Recent Developments
12.13 Shanghai Hile Biological
12.13.1 Shanghai Hile Biological Corporation Information
12.13.2 Shanghai Hile Biological Overview
12.13.3 Shanghai Hile Biological Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.13.4 Shanghai Hile Biological Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.13.5 Shanghai Hile Biological Recent Developments
12.14 Liaoning Yikang Biological
12.14.1 Liaoning Yikang Biological Corporation Information
12.14.2 Liaoning Yikang Biological Overview
12.14.3 Liaoning Yikang Biological Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.14.4 Liaoning Yikang Biological Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.14.5 Liaoning Yikang Biological Recent Developments
12.15 Jilin Zhengye Biological Product
12.15.1 Jilin Zhengye Biological Product Corporation Information
12.15.2 Jilin Zhengye Biological Product Overview
12.15.3 Jilin Zhengye Biological Product Inactivated Porcine Parvovirus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
12.15.4 Jilin Zhengye Biological Product Inactivated Porcine Parvovirus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
12.15.5 Jilin Zhengye Biological Product Recent Developments
13 Industry Chain and Sales Channels Analysis
13.1 Inactivated Porcine Parvovirus Vaccine Industry Chain Analysis
13.2 Inactivated Porcine Parvovirus Vaccine Key Raw Materials
13.2.1 Key Raw Materials
13.2.2 Raw Materials Key Suppliers
13.3 Inactivated Porcine Parvovirus Vaccine Production Mode & Process
13.4 Inactivated Porcine Parvovirus Vaccine Sales and Marketing
13.4.1 Inactivated Porcine Parvovirus Vaccine Sales Channels
13.4.2 Inactivated Porcine Parvovirus Vaccine Distributors
13.5 Inactivated Porcine Parvovirus Vaccine Customers
14 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
14.1 Inactivated Porcine Parvovirus Vaccine Industry Trends
14.2 Inactivated Porcine Parvovirus Vaccine Market Drivers
14.3 Inactivated Porcine Parvovirus Vaccine Market Challenges
14.4 Inactivated Porcine Parvovirus Vaccine Market Restraints
15 Key Finding in The Global Inactivated Porcine Parvovirus Vaccine Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer